Ocrevus

Chemical Nameocrelizumab
Dosage FormInjection (intravenous; 300 mg/10 ml)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyGenentech Inc.
Approval Year2017

Indication

  • To treat relapsing forms of multiple sclerosis in adults.
  • To treat primary progressive multiple sclerosis in adults
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ocrevus (Ocrelizumab) Prescribing Information2017Genentech USA, Inc., South San Francisco, CA